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Consequences of hyperphosphatemia in patients with end-
stage renal disease (ESRD). Hyperphosphatemia is invariably
present among patients with end-stage renal disease (ESRD)
and is becoming an increasingly important clinical entity. De-
spite concerted efforts by patients, dietitians, and nephrologists
to control serum phosphorus, a recent study by Block et al
found that more than 60% of patients on hemodialysis in the
United States have serum phosphorus levels above the recom-
mended goal of 5.5 mg/dL. Historically, nephrologists have been
concerned about the central role of elevated serum phospho-
rus in the pathogenesis of secondary hyperparathyroidism and
extraosseous calcification. However, the consequences of un-
treated hyperphosphatemia have assumed more importance in
the last few years, largely due to recent clinical studies that
revealed a more sinister role of elevated serum phosphorus
in increasing the mortality risk among patients with ESRD.
Hemodialysis patients with serum phosphorus greater than
6.5 mg/dL were reported to have a 27% higher mortality
risk than patients with serum phosphorus between 2.4 and
6.5 mg/dL. The pathophysiologic mechanisms by which persis-
tent hyperphosphatemia enhances the mortality risk in dial-
ysis patients are not yet completely understood. However,
given that inadequate control of serum phosphorus contributes
to elevated calcium-phosphorus product (Ca × P), untreated
hyperphosphatemia may play a key role in cardiovascular
calcification. In response to these findings, the National Kid-
ney Foundation Kidney Disease Outcome Quality Initiative
(K/DOQI) Clinical Practice Guidelines for Bone Metabolism
and Disease in Chronic Kidney Disease have recently recom-
mended more stringent levels for controlling serum phosphorus
and Ca × P product in order to improve patients’ quality of life
and longevity.
CONSEQUENCES OF HYPERPHOSPHATEMIA
Chronic kidney disease is becoming a worldwide prob-
lem. The United States Renal Data System (USRDS) es-
timated that there are more than 300,000 patients with
end-stage renal disease (ESRD) in the United States
[1]. Hyperphosphatemia is invariably present among
patients with ESRD and is becoming an increasingly
important clinical entity (Table 1). Despite concerted
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efforts by patients, dietitians, and nephrologists to con-
trol serum phosphorus, a recent study by Block et al [2]
found that more than 60% of patients on hemodialy-
sis in the United States have serum phosphorus levels
above the recommended goal of 5.5 mg/dL. Nephrolo-
gists have always appreciated the central role of elevated
serum phosphorus in the pathogenesis of secondary hy-
perparathyroidism. However, recent clinical studies re-
vealed that patients with serum phosphorus greater than
6.5 mg/dL have a 27% higher mortality risk than those
with phosphorus levels between 2.4 and 6.5 mg/dL [2].
The pathophysiologic mechanisms by which persistent
hyperphosphatemia enhances the mortality risk in dialy-
sis patients are not yet completely understood. However,
given that inadequate control of serum phosphorus con-
tributes to elevated calcium-phosphorus product (Ca ×
P), untreated hyperphosphatemia may play a key role in
soft tissue and cardiovascular calcification. As a result, the
National Kidney Foundation Kidney Disease Outcome
Quality Initiative (K/DOQI) Clinical Practice Guidelines
for Bone Metabolism and Disease in Chronic Kidney Dis-
ease have recommended more stringent levels for con-
trolling serum phosphorus and Ca × P product in order
to improve patients’ quality of life and longevity (Table 2)
[3]. The aim of the present update is to review findings
from recent clinical and experimental studies that con-
tributed greatly to our increased understanding of the
pathophysiologic consequences of untreated hyperphos-
phatemia in patients with ESRD.
SECONDARY HYPERPARATHYROIDISM
(SHPT)
Nephrologists have known for decades that persistent
hyperphosphatemia plays a key role in the pathogenesis
of SHPT. Initially, hyperphosphatemia was thought to in-
directly increase parathyroid hormone (PTH) secretion
as a result of reducing serum calcium level by one or more
of three possible mechanisms. First, high serum phospho-
rus may cause calcium precipitation in soft tissues. Sec-
ond, it may also decrease the efflux of calcium from bone
as a result of increasing resistance of bone to PTH ac-
tion. Third, it also inhibits the 1 a-hydroxylase enzyme,
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Table 1. Consequences of hyperphosphatemia
Hypocalcemia
Decreased calcitriol level
Secondary hyperparathyroidism
Extraosseous calcification
Soft tissue calcification
Hemodynamic disturbances
Vascular and coronary calcification
Myocardial calcification
Cardiac valve calcification
Calciphylaxis
Increased morbidity and mortality
Table 2. Guidelines for management of mineral metabolism
Block and Port 2000 K/DOQI Guidelines 2003
Serum phosphorus level Goal phosphorus level
3.5–5.5 mg/dL 3.5–5.5 mg/dL
Serum calcium level Goal serum calcium
9.2–9.6 mg/dL 8.4–9.5 mg/dL
Ca × P product <55 mg2/dL2 Goal Ca × P product <55 mg2/dL2
Intact PTH 100 to 200 pg/mL Goal intact PTH 150 to 300 pg/mL
leading to further reduction in the already decreased 1,
25(OH)2D3 level (calcitriol) [4]. Low calcitriol levels re-
sults in decreased intestinal absorption of calcium and
hypocalcemia, which in turn stimulates secretion of PTH
through its interaction with calcium-sensing receptor in
the parathyroid gland.
Recent evidence, however, suggests a direct effect of
phosphorus on the production of PTH, independent of
serum calcium and calcitriol effects [5]. Dietary phos-
phorus restriction in uremic rats inhibits parathyroid cell
proliferation by a mechanism that is probably indepen-
dent of the effects of calcium and calcitriol [6]. Similarly,
low phosphate diet in dogs with experimental chronic re-
nal failure led to decreased PTH level and prevented the
development of SHPT, independent of changes in serum
ionized calcium and calcitriol level [7]. Clinical studies in
patients with chronic renal failure also showed that di-
etary phosphate restriction reduced PTH levels and im-
proved SHPT independent of serum ionized calcium and
calcitriol level [8].
In vitro studies have also shown a direct effect of phos-
phorus on parathyroid glands. Incubation of intact rat
parathyroid glands [9] or bovine parathyroid gland slices
[10] in a high phosphorus medium resulted in signifi-
cant increase in PTH secretion by a post-transcriptional
mechanism. High phosphorus level apparently does not
increase the rate of gene transcription, but rather, may re-
duce the rate of degradation of PTH mRNA [11]. More-
over, Cozzolino et al [12] showed that phosphorus may
induce hyperplasia of the parathyroid glands by activat-
ing the transforming growth factor-a (TGF-a). The mech-
anism by which phosphorus enhances PTH secretion,
however, is not completely understood but may be related
to reduced intracellular calcium concentration, which in
turn decreases prostaglandin production and secondarily
stimulates PTH secretion [13].
CARDIOVASCULAR CALCIFICATION
Cardiovascular disease (CVD) remains the major mor-
tality risk in dialysis patients, accounting for almost 50%
of deaths among these patients [14, 15]. The burden of
cardiovascular disease is even greater in older diabetic
patients, who now represent the main patient population
contributing to the increasing incidence of ESRD in the
United States. Hyperphosphatemia and elevated Ca ×
P product are associated with cardiovascular calcifica-
tion, including the aorta, carotid and coronary arteries,
the cardiac valves, as well as the myocardial muscle. The
role of hyperphosphatemia in the pathogenesis of soft
tissue calcification is discussed in detail by another arti-
cle in this supplement (Alfrey). In the following section,
I will review the hemodynamic consequences of hyper-
phosphatemia and the role of elevated serum phospho-
rus in pathogenesis of vascular calcification, as well as
calcification of the myocardium and cardiac valves.
Hemodynamic disturbances
Marchais et al [16] described significant hemody-
namic alterations associated with hyperphosphatemia in
patients with ESRD. These authors reported that hy-
perphosphatemia was associated with increased cardiac
stroke index, increased systolic and decreased diastolic
blood pressure, increased pulse pressure, and increased
pulse wave velocity [16, 17]. Moreover, patients with
hyperphosphatemia had higher common carotid artery
diameter and lower wall-to-lumen ratios. The authors
speculated that these changes were caused by calcifica-
tion of the media of the arterial wall, which in turn led to
arterial stiffness. These hemodynamic disturbances may
result in left ventricular hypertrophy, and also compro-
mise coronary artery blood flow during diastole. It is note-
worthy that in the Framingham Heart Study, abdominal
aortic calcification identified by plain radiographs was in-
dependently predictive of subsequent vascular morbidity
and mortality [18].
Coronary artery and myocardial calcification
Another consequence of hyperphosphatemia in
patients with ESRD is widespread calcification of the
cardiovascular system, including the myocardium, con-
ducting system, cardiac valves, and coronary arteries. Car-
diovascular calcification has been linked to an increased
risk of cardiovascular events, including myocardial in-
farction, fatal arrhythmia, congestive heart failure, and
valvular heart disease [19, 20]. Coronary artery calcifi-
cation (CAC) is absent in normal vessels, but usually
occurs when atherosclerosis is present and is consid-
ered an integral part of the atherosclerotic plaque. More-
over, CAC scores correlate with histologic, intravascular
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Table 3. Cardiovascular disease risk factors in CKD patients
Traditional risk factors Uremia-related risk factors
Older age Hyperphosphatemia
Male sex Increased Ca × P product
Hypertension High PTH levels
Diabetes Vitamin D therapy
Smoking ?Calcium daily load
High LDL cholesterol Inflammation (CRP)
Low HDL cholesterol Oxidative stress
Hyperhomocysteinemia Malnutrition
Physical inactivity Volume overload
Family history of CVD Chronic anemia
LVH Albuminuria
Menopause Infrequent use of ASA, B-blockers,
and lipid-lowering agents
Genetic predisposition
ultrasound, and angiographic measurements of CAC [21,
22]. Recent studies have clearly shown that patients with
ESRD on dialysis have a higher prevalence and severity
of CAC than healthy subjects of the same age and gen-
der. The causes of CAC in patients with chronic kidney
disease (CKD) are currently under intense investigation.
In addition to the traditional CVD risk factors, studies in
dialysis patients have shown a correlation between CAC
and a number of dialysis-related factors, such as dialysis
vintage, hyperphosphatemia, high Ca × P product, and
vitamin D therapy (Table 3) [20]. Braun et al [23] re-
ported that the CAC scores were 2.5- to 5-fold higher in
the dialysis patients than in the nondialysis patients with
documented or suspected history of CAC, all of whom
underwent coronary angiography. Age and hypertension
were correlated with a higher incidence of calcification,
whereas no correlation was noted between serum cal-
cium, serum phosphorus, Ca × P product, or PTH levels.
On the other hand, Goodman et al [24] compared the
prevalence of CAC in 39 young hemodialysis patients
versus 60 normal subjects using electron-beam computed
tomography (EBCT). They found that factors associated
with a higher incidence of CAC included increased mean
serum phosphorus concentration, mean Ca × P prod-
uct, and daily calcium intake. Hyperphosphatemia was
clearly shown to be an independent risk factor for death
[2]. This is predominantly from cardiovascular disease.
Indeed, Ganesh et al [27] suggested that serum phospho-
rus >6.5 mg/mL is a cardiotoxin, and along with a Ca × P
product exceeding 72 mg2/dL2, predisposes to cardiovas-
cular calcification [27]. These observations clearly indi-
cate that additional studies are needed to further clarify
whether high phosphorus level is involved in the patho-
genesis of intimal, medial, or soft tissue calcification.
The molecular mechanisms regulating active vascular
calcification remain unknown. In an in vitro model, high
phosphorus levels similar to those regularly seen in dial-
ysis patients in the incubation medium directly enhanced
extracellular calcification in human aortic smooth muscle
cells via a sodium-dependent phosphate cotransporter-
sensitive mechanism [26]. Moreover, high phosphorus
levels increased the expression of the osteoblast-specific
genes Cbfa-1 and osteocalcin. Thus, high phosphorus
seems to stimulate osteoblastic differentiation of vascu-
lar smooth muscle cells and directly enhance extracellular
calcification by these cells [27]. Therefore, it appears that
high serum phosphorus plays a key role in the increased
prevalence of cardiovascular calcification in patients with
ESRD.
CARDIAC VALVE CALCIFICATION
Calcification of the aortic and mitral valves was 8-
fold more frequent in patients with ESRD than in the
age-matched control population [28]. The prevalence of
mitral valve calcification in hemodialysis patients and
in age-matched control patients was 45.5% versus 10%,
while aortic valve calcification was 54% versus 4.3%,
respectively [29]. Patients with valve calcification were
more commonly diabetic and had higher levels of serum
phosphorus and Ca × P product [30]. Three interesting
characteristics of valve calcification in dialyzed patients
have been reported: first, valve calcification progresses
rapidly and results in valve dysfunction within a few years
[30]. Second, the presence of valve calcification correlates
with coronary and myocardial calcification [24]. Finally,
cardiac valve calcification may lead to heart failure, coro-
nary ischemia, arrhythmias, valve stenosis, increased risk
of infective endocarditis, and thromboembolic events [24,
30]. Moreover, valve calcification was independently pre-
dictive of an increased all-cause mortality as well as car-
diovascular death [31].
CALCIPHYLAXIS
Calciphylaxis, or calcific uremic arteriolopathy (CUA),
is a serious complication infrequently encountered in pa-
tients with ESRD on dialysis. It is characterized by painful
reddish nodules or plaques that often progress to ulcer-
ation, infection, sepsis, and death. The lesions are most
commonly encountered on the lower extremities, thighs,
buttocks, and abdomen. Histologic examination of the le-
sions revealed arteriolar calcification of the subcutaneous
fat and dermis. Interestingly, these lesions may progress
more rapidly and may cause higher mortality than other
forms of vascular calcification [32]. Indeed, the mortality
rate in CUA ranges from 45% to 65% and is even higher
when the lesions ulcerate [33].
The risk factors for CUA are not clearly established.
However, several factors have been implicated (Table 4).
Although elevated PTH level was thought to be a likely
culprit, and parathyroidectomy was adopted as a classic
therapeutic intervention, recent evidence suggests that
hyperparathyroidism is not essential for the development
of CUA [34]. By contrast, hyperphosphatemia was found
to increase the risk for CUA [35–37]. Mazhar et al [35]
reported a 3.5-fold increase in the risk of CUA in asso-
ciation with each mg/dL increase in serum phosphorus
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Table 4. Risk factors implicated in the development of CUA
Female gender
Caucasian race
Obesity
High PTH level
Hyperphosphatemia
High Ca × P product
Hypoalbuminemia
Coumadin
Table 5. Causes of death in dialysis patients
Cause of death Percent
Cardiac 49%
Infection 15%
Cerebrovascular 6%
Malignancy 4%
Other known causes 19%
Unknown 7%
Adapted from Sarnak et al, Semin Dial 12:69–76, 1999.
level. It has therefore been speculated that cures after
parathyroidectomy may be the result of significant de-
cline in serum phosphorus level due to “hungry bone”
syndrome [32]. Patients with calciphylaxis have an 8-fold
increased risk of death compared with control patients
[35]. Therefore, control of serum phosphorus and Ca × P
product may prove to be critical in preventing this deadly
disease.
INCREASED MORTALITY RISK
The average annual mortality rate among the dialysis
population in the United States is the highest in the indus-
trialized world, approaching 20%. As can be seen from
Table 5, approximately one half of deaths are attributed
to cardiovascular disease [14]. Foley et al [15] found that
compared to age- and sex-matched individuals from the
general population dialysis patients have 2- to 100-fold
greater risk of mortality, particularly in the young. The
National Kidney Foundation guidelines for chronic kid-
ney disease (CKD) state that patients with CKD should
be considered in the highest risk group for CVD [38]. Rel-
evant to this statement are emerging data that strongly
suggest that disturbances in mineral metabolism con-
tribute to the development of CVD and the increased
mortality in dialysis patients.
Reports of an association between high serum phos-
phorus in patients with ESRD and increased mortal-
ity risk have led to a dramatic impact on our approach
to treatment strategies of hyperphosphatemia. Lowrie
and Lew found a two-fold higher risk of death for their
hemodialysis patients with serum phosphorus greater
than 7 mg/dL relative to those patients with a level be-
tween 5 and 7 mg/dL [39]. More recently, data from two
large, national, randomized, cross-sectional samples of
hemodialysis patients who received dialysis for at least
one year (N = 6407) revealed that patients with a serum
phosphorus level >6.5 mg/dL had a 27% higher mortality
Table 6. Mechanisms of increased mortality risk secondary to
hyperphosphatemia
Increased intima-media thickness and arterial stiffness of large arteries
Hemodynamic disturbances
Increased cardiac stroke index and heart rate
Increased systolic blood pressure
Decreased diastolic blood pressure
Increased pulse pressure
Increased pulse wave velocity
Cardiovascular calcification
Coronary artery calcification leading to ischemia and
myocardial infarction
Valve calcification leading to valve dysfunction and congestive
heart failure
Myocardial calcification leading to disruption of normal conduction
Cardiac arrhythmia
Sudden death
risk than patients with serum phosphorus levels of 2.4 to
6.5 mg/dL [2]. Calcium-phosphate product (Ca × P) in
excess of 72 mg2/dL2 was also associated with a relative
risk (RR) of mortality of 1.34 (P < 0.01) compared with
patients with a Ca × P between 42 and 52 mg2/dL2. Be-
cause serum calcium concentrations were not directly as-
sociated with an increased risk of death, the mortality risk
associated with increased Ca × P product was thought to
be driven primarily by serum phosphorus. Of concern was
that approximately 40% of patients had serum phospho-
rus greater than 6.5 mg/dL, and almost 70% had a phos-
phorus level >5.5 mg/dL. The authors recommend more
vigorous control of serum phosphorus to levels between
2.5 and 5.5 mg/dL, while maintaining Ca × P product less
than 55 mg2/dL2 [2, 40]. Indeed, the recent National Kid-
ney Foundation Kidney Disease Outcome Quality Ini-
tiative (K/DOQI) Clinical Practice Guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease have
adopted the recommendation for controlling serum phos-
phorus and Ca × P product to these stringent levels in
order to improve patients’ quality of life and longevity
(Table 2) [3].
Although the mechanism responsible for the increased
risk of death in patients with hyperphosphatemia was
unknown, it was thought to be cardiovascular in nature
(Table 6). This was substantiated by a recent study that
evaluated the relationship between hyperphosphatemia
and cardiac mortality [25]. This study, which analyzed
data from a cohort of randomly selected hemodialysis pa-
tients (N = 12,833), found that elevations in serum phos-
phorus >6.5 mg/dL, Ca × P product >70 mg2/dL2, and
serum PTH levels >495 pg/mL were strongly associated
with an increased risk of cardiac mortality in hemodialysis
patients.
CONCLUSION
The foregoing review shows that, left untreated, hyper-
phosphatemia plays a major role in SHPT, extraosseous
calcification, and increased risk of death mainly from
cardiovascular disease. Consequently, nephrologists must
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strive to achieve control of serum phosphorus. The new
National Kidney Foundation K/DOQI Clinical Practice
Guidelines for Bone Metabolism and Disease in Chronic
Kidney Disease have recommended more stringent lev-
els for controlling serum phosphorus and Ca × P product
in order to improve patients’ quality of life and longevity.
These guidelines, although with limitations, were de-
signed to assist decision-making by nephrologists in order
to improve patients’ quality of life and longevity. Under-
standing the consequences of hyperphosphatemia in pa-
tients with ESRD and implementing the most cost-ef-
fective therapy are important first steps in this direction.
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